Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 835 of 5804
-
Stem cells injected into eye aim to halt blindness
Disease control OngoingThe main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, an…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New chemo combo may lower death risk in child stem cell transplants
Disease control CompletedThe aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan compared to the conventional (myeloablative) dose of i.v. Busulfan, each administered as part of a standardised Fludarabine-containing conditioning regimen and to contribute to a PK model…
Phase: PHASE2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Ketamine shows promise for rapid relief of suicidal ideation
Symptom relief CompletedThe primary objective of this study is to assess the efficacy of ketamine versus a placebo for the short-term (at 72h, i.e. 24h after the last perfusion) relief of suicidal ideation, measured using the BSS hetero questionnaire, in patients hospitalized for suicide risk.
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Immune booster shows promise against rare cancer
Disease control CompletedThis phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell de…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can extra rituximab keep vasculitis at bay?
Disease control CompletedMAINRITSAN study compared Rituximab and azathioprine as maintenance therapy for ANCA-associated vasculitides. In this study, Rituximab (5 infusions at D1, D15, M6, M12, M18) was superior to azathioprine (2 mg/kg/day) to prevent relapses of AAV 28 months after the inclusion (Guill…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New combo therapy aims to halt returning prostate cancer
Disease control CompletedThe primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to standard-of-care salvage radiation therapy to allow for furthe…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Immunotherapy combo shows promise in reducing head and neck cancer recurrence
Disease control CompletedThe goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surg…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat their cancer. In these transplants, chemotherapy and …
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for kids with tough cancers: immunotherapy drug tested
Disease control Recruiting nowResearchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means c…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for tough lymphoma: targeted drug shows promise in Mid-Stage trial
Disease control OngoingThe purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a common blood thinner stop silent heart attacks?
Disease control CompletedHeart attacks are most commonly caused by rupture of fatty deposits (plaques) within the wall of heart blood vessels. It appears that this process can also frequently occur without causing any symptoms and these events likely explain the development of narrowing within the heart …
Phase: PHASE2, PHASE3 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
RNA vaccine shows promise in advanced melanoma trial
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to determine the safety and tolerability of intravenous administration of a tetravalent RNA-lipoplex cancer vaccine targeting four tumor-associated antigens in patients with advanced melanoma.
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:01 UTC
-
Hand transplants get a boost: new drug may reduce rejection risk
Disease control Recruiting nowThe purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in …
Phase: PHASE2 • Sponsor: Linda Cendales • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy shows promise for aggressive blood cancer
Disease control CompletedThe purpose of phase 1 part in this study was to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newl…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase II trial studies how well pembrolizumab alone or with idelalisib or ibrutinib works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas that have returned after a period of improvement (relapsed) or have not responded …
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Donor T-Cells take on stubborn CMV in transplant patients
Disease control OngoingThis phase II trial studies how well donor cytomegalovirus-specific cytotoxic T-lymphocytes work in treating patients with a cytomegalovirus infection that has come back or has not gotten better despite standard therapy. White blood cells from donors who have been exposed to cyto…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New heart valve replacement offers hope for high-risk patients
Disease control OngoingStudy to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system
Phase: NA • Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cocktail aims to tame incurable head and neck cancer
Disease control OngoingThe purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug cocktails show promise for multiple myeloma patients
Disease control CompletedThis study will evaluate the safety and the efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (CCyd) or lenalidomide and dexamethasone (CRd) followed by autologous transplantation ASCT or 12 cycles of carfilzomib combined with dexamethasone and lenalidomide…
Phase: PHASE2 • Sponsor: Mario Boccadoro • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Ovarian cancer vaccine trial aims to keep tumors at bay
Disease control OngoingThe goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is "Will participants who receive treatment with Vigil h…
Phase: PHASE2 • Sponsor: Gradalis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC